Biogen Inc. $BIIB Stock Acquired by Mather Group LLC.

Mather Group LLC. increased its holdings in Biogen Inc. (NASDAQ:BIIB) by 2,194.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 36,433 shares of the biotechnology company’s stock after buying an additional 34,845 shares during the quarter. Mather Group LLC.’s holdings in Biogen were worth $8,229,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Fortitude Family Office LLC grew its stake in shares of Biogen by 187.9% in the 3rd quarter. Fortitude Family Office LLC now owns 907 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 592 shares during the period. Triumph Capital Management lifted its position in shares of Biogen by 20,800.0% during the 3rd quarter. Triumph Capital Management now owns 209 shares of the biotechnology company’s stock worth $47,000 after buying an additional 208 shares during the period. First Citizens Bank & Trust Co. bought a new position in shares of Biogen during the 3rd quarter worth approximately $8,844,000. B. Riley Wealth Advisors Inc. lifted its position in shares of Biogen by 439.7% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 11,301 shares of the biotechnology company’s stock worth $2,553,000 after buying an additional 9,207 shares during the period. Finally, Polaris Financial Partners acquired a new stake in Biogen in the 3rd quarter valued at $109,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $232.83 on Thursday. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $238.24. The company has a 50 day moving average of $218.89 and a 200-day moving average of $203.29. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a market cap of $34.40 billion, a price-to-earnings ratio of 41.21, a PEG ratio of 2.53 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. Biogen’s revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts forecast that Biogen Inc. will post 12.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BIIB. Wedbush upped their price target on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, July 30th. Citigroup increased their price objective on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Mizuho lifted their price objective on Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $236.04.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.